Mitomycin-C Injection: Product Description and Uses
Mitomycin-C is an antineoplastic agent derived from the bacterium Streptomyces caespitosus. It is primarily used in the treatment of various types of cancer, including bladder cancer, gastric cancer, and pancreatic cancer. Mitomycin-C works by inhibiting DNA synthesis, leading to cell death, particularly in rapidly dividing cancer cells. It is often used in combination with other chemotherapy agents to enhance its effectiveness.
Uses of Mitomycin-C
- Bladder Cancer: Used as an intravesical therapy for superficial bladder tumors.
- Gastric Cancer: Administered as part of a combination chemotherapy regimen for advanced gastric cancer.
- Pancreatic Cancer: Utilized in combination with other chemotherapeutic agents for treating pancreatic adenocarcinoma.
- Other Cancers: May be used off-label for various other malignancies, depending on the clinical scenario.
Technical Data
| Parameter | Details |
|---|---|
| Generic Name | Mitomycin-C |
| Brand Name | Mutamycin, others |
| Drug Class | Antineoplastic agent |
| Formulation | Injection (lyophilized powder) |
| Dosage Forms | 5 mg, 10 mg, 20 mg |
| Administration Route | Intravenous (IV) or intravesical |
| Mechanism of Action | Alkylating agent that cross-links DNA |
| Indications | Bladder cancer, gastric cancer, pancreatic cancer |
| Storage Conditions | Store at room temperature, protect from light |
| Side Effects | Nausea, vomiting, myelosuppression, pulmonary toxicity |
| Contraindications | Hypersensitivity to mitomycin, pregnancy, breastfeeding |
| Drug Interactions | May interact with other cytotoxic agents and anticoagulants |
Key Points
- Administration: Mitomycin-C is typically administered by a healthcare professional, either intravenously or directly into the bladder.
- Monitoring: Patients receiving Mitomycin-C require regular monitoring for side effects, particularly blood counts and signs of pulmonary toxicity.
- Precautions: Due to its potential for severe side effects, it is crucial to follow dosing guidelines and monitor for adverse reactions closely.
Mitomycin-C remains a vital component in the oncological treatment arsenal, particularly for specific cancers where its efficacy has been well established.